Age of onset moderates the effects of Vascular Risk Factors on Neurodegeneration, Blood-Brain-Barrier permeability, and cognitive decline in Alzheimer’s Disease

Table 1 Demographics, clinical characteristics, and CSF dosages of patients included in the cross-sectional cohort

	EOAD (n = 84)	cLOAD (n = 178)	vLOAD (n = 106)	p
Age (years)	59.44 ± 3.73	70.11 ± 3.10	78.96 ± 3.08	< 0.001***
Sex (%F)	42.85%	48.31%	52.83	0.393
APOE (%ε4)	45.23%	47.75%	37.73%	0.323
MMSE	19.74 ± 7.01	20.70 ± 5.32	20.55 ± 5.55	0.522
p-tau/Aβ42	0.20 ± 0.12	0.21 ± 0.14	0.21 ± 0.11	0.633
t-tau (pg/ml)	500.74 ± 353.68	511.96 ± 317.59	517.41 ± 337.00	0.941
Qalb	8.06 ± 4.72	7.39 ± 4.31	7.36 ± 3.97	0.398
Vascular Score	0.168 ± 0.127	0.237 ± 0.197	0.252 ± 0.197	0.004**

Legend. EOAD: early-onset AD (< 65 yo); cLOAD: classical onset AD (65–75 yo); vLOAD: late-onset AD (> 75 yo); F: female; APOE: Apolipoprotein E; MMSE: Mini-Mental State Examination; Qalb: albumin quotient; p: p-value. Bold values represent significativity (**= <0.01; ***= <0.001)

ISSN: 1758-9193